Cargando…

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. METHODS: Patients received oral dovitinib 500 mg day(−1), 5 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joensuu, Heikki, Blay, Jean-Yves, Comandone, Alessandro, Martin-Broto, Javier, Fumagalli, Elena, Grignani, Giovanni, Del Muro, Xavier Garcia, Adenis, Antoine, Valverde, Claudia, Pousa, Antonio Lopez, Bouché, Olivier, Italiano, Antoine, Bauer, Sebastian, Barone, Carlo, Weiss, Claudia, Crippa, Stefania, Camozzi, Maura, Castellana, Ramon, Le Cesne, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672922/ https://www.ncbi.nlm.nih.gov/pubmed/28850565 http://dx.doi.org/10.1038/bjc.2017.290

Ejemplares similares

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
por: Bouché, Olivier, et al.
Publicado: (2018)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
por: Pantaleo, Maria A., et al.
Publicado: (2022)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
por: Hidalgo-Ríos, Samuel, et al.
Publicado: (2022)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions
por: Bauer, Sebastian, et al.
Publicado: (2015)

Pilot study of dovitinib in patients with von Hippel-Lindau disease
por: Pilié, Patrick, et al.
Publicado: (2018)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus
por: Álvarez Álvarez, Rosa, et al.
Publicado: (2019)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Dovitinib induces mitotic defects and activates the G(2) DNA damage checkpoint
por: Man, Wing Yu, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
por: Shivapurkar, Narayan, et al.
Publicado: (2017)

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
por: Yadav, Shalini S., et al.
Publicado: (2017)

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies
por: Taylor, Matthew H., et al.
Publicado: (2020)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
por: Chen, Zhi-Yuan, et al.
Publicado: (2012)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study
por: Frezza, Anna Maria, et al.
Publicado: (2022)

Targeting the VEGF Pathway in Osteosarcoma
por: Assi, Tarek, et al.
Publicado: (2021)

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
por: Gronchi, Alessandro, et al.
Publicado: (2019)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro
por: Lee, Yura, et al.
Publicado: (2016)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
por: Gaur, Shikha, et al.
Publicado: (2014)

Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model
por: Kähkönen, Tiina E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i8a9mou8j5aspncmhqhvv4qu5f